ÂÜÀòÂÒÂ×

Kathleen Clarence-Smith is a seasoned leader in the pharmaceutical and biotechnology sectors with extensive experience in neurology and drug development. As Co-Founder and Board Chair of CHASE THERAPEUTICS since 2017, Kathleen focuses on treatments for anhedonia, depression, and Parkinson's Disease. Kathleen also serves as Co-Founder and Partner at KM Pharmaceutical Consulting, LLC, offering project management services since 2007. Previously, Kathleen held key positions in various organizations, including Chief Medical Officer at Chase Pharmaceuticals, where a new Alzheimer's treatment was developed, and roles such as President and CEO at Prestwick Pharmaceuticals, where a contract research organization in medicinal chemistry was founded. Early career experiences include leadership roles at Otsuka Pharmaceutical Companies and Roche, followed by foundational medical research during a postdoctoral fellowship at Johns Hopkins School of Medicine. Kathleen's educational background includes a Ph.D. in Neuroscience and an M.D. in Medicine from the University of Tours, France, along with board certification in Neurology.